BioDiem Ltd - Product Pipeline Review - 2014

Published: Jan, 2014 | Pages: 29 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Summary

Global Market Direct's pharmaceuticals report, "BioDiem Ltd - Product Pipeline Review - 2014" provides data on the BioDiem Ltd's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, BioDiem Ltd's corporate website, SEC filings, investor presentations and featured press releases, both from BioDiem Ltd and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- BioDiem Ltd - Brief BioDiem Ltd overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of BioDiem Ltd human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of BioDiem Ltd with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the BioDiem Ltd's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate BioDiem Ltd's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of BioDiem Ltd in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the BioDiem Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with BioDiem Ltd.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of BioDiem Ltd and identify potential opportunities in those areas.

 Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
BioDiem Ltd Snapshot 4
BioDiem Ltd Overview 4
Key Information 4
Key Facts 4
BioDiem Ltd - Research and Development Overview 5
Key Therapeutic Areas 5
BioDiem Ltd - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
BioDiem Ltd - Pipeline Products Glance 10
BioDiem Ltd - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
BioDiem Ltd - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
BioDiem Ltd - Drug Profiles 14
Live Attenuated Influenza Vaccine 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
BDM-E 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
BDM-I 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Hepatitis B Vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Hepatitis D Vaccine 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
BioDiem Ltd - Pipeline Analysis 20
BioDiem Ltd - Pipeline Products by Therapeutic Class 20
BioDiem Ltd - Pipeline Products by Route of Administration 22
BioDiem Ltd - Pipeline Products by Molecule Type 23
BioDiem Ltd - Recent Pipeline Updates 24
BioDiem Ltd - Dormant Projects 26
BioDiem Ltd - Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29

List of Tables
BioDiem Ltd, Key Information 4
BioDiem Ltd, Key Facts 4
BioDiem Ltd - Pipeline by Indication, 2014 7
BioDiem Ltd - Pipeline by Stage of Development, 2014 8
BioDiem Ltd - Monotherapy Products in Pipeline, 2014 9
BioDiem Ltd - Phase II, 2014 10
BioDiem Ltd - Phase I, 2014 11
BioDiem Ltd - Preclinical, 2014 12
BioDiem Ltd - Discovery, 2014 13
BioDiem Ltd - Pipeline by Therapeutic Class, 2014 21
BioDiem Ltd - Pipeline by Route of Administration, 2014 22
BioDiem Ltd - Pipeline by Molecule Type, 2014 23
BioDiem Ltd - Recent Pipeline Updates, 2014 24
BioDiem Ltd - Dormant Developmental Projects,2014 26
BioDiem Ltd, Subsidiaries 27